T-lymphocyte cell therapy - Green Cross Cell

Drug Profile

T-lymphocyte cell therapy - Green Cross Cell

Alternative Names: Activated T-lymphocytes - Green Cross Cell; Activated T-lymphocytes - Innocell; Immuncell-LC; Inno-LC-01; T-lymphocyte cell therapy - Innocell

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innocell Corporation
  • Developer Green Cross Cell
  • Class Antineoplastics; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatocellular carcinoma
  • Phase III Glioblastoma
  • No development reported Cervical cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 04 Jul 2017 Green Cross Cell completes a phase II trial for Hepatocellular carcinoma (Adjuvant therapy) in South Korea (IV) (NCT01897610)
  • 16 Dec 2016 Biomarkers information updated
  • 12 Oct 2016 Phase III development is ongoing for Glioblastoma in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top